• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

101
12
11
11
7

COUNTRY

12
4
1
1
1

PRICE

491
492
499
574

PUBLISHED

0
3
6
574

PRODUCT TYPE

482
92

Lung Cancer

Lung cancer is the most common cause of cancer-related death in men and women around the world, accounting for well over a million deaths every year. Unsurprisingly therefore, keen competition exists among the world’s leading pharmaceuticals and niche players. The Lung Cancer Section features expert reports exploring markets and the competitive landscape for drugs, therapeutics, medical technologies, biomarkers, etc. worldwide; the epidemiology of lung cancer including risk factors and current/future mortality rates; as well as disease specific reports featuring advanced lung cancer, small-cell lung cancer and non-small-cell lung cancer. Whether you are looking to invest or expand into the lung cancer pharmaceutical market, sourcing a new provider or simply looking for the latest market data, your search begins here… Show Less Read more

PRODUCT TITLE
Lung Cancer Drug Pipeline Update 2014 Lung Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Lung Cancer Drug Pipeline Update 2014

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D...

July 2014
FROM
Lung Cancer Drug Pathway Analyzer 2014 Lung Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Lung Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 487 targeted molecular therapies known to affect more than 254 specific intracellular signaling pathways...

July 2014
FROM

Lung Cancer Treatment Drugs Markets in China

China's demand for Lung Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

June 2014
FROM
Analytical Tool - Lung Cancer Analytical Tool - Lung Cancer - Product Thumbnail Image

Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2014". According...

March 2014

Europe Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

January 2014
FROM

US Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

November 2013
FROM
Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Apoptosis Triple Analysis: Lung Cancer, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Leukemia, Lung Cancer and Melanoma Triple Analysis: Leukemia, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Leukemia, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Angiogenesis Triple Analysis: Lung Cancer, Melanoma and Angiogenesis - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Protein Kinase Inhibitors Triple Analysis: Lung Cancer, Melanoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts...

June 2013
FROM
Triple Analysis: Lung Cancer, Lymphoma and Melanoma Triple Analysis: Lung Cancer, Lymphoma and Melanoma - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Antibodies Triple Analysis: Lung Cancer, Melanoma and Antibodies - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Breast Cancer, Lung Cancer and Melanoma Triple Analysis: Breast Cancer, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Global Lung Cancer Pipeline Capsule - 2013 Global Lung Cancer Pipeline Capsule - 2013 - Product Thumbnail Image

Global Lung Cancer Pipeline Capsule - 2013

Fore Pharma's latest report ‘Global Lung Cancer Pipeline Capsule – 2013' provides up-to-date information on key Research and Development (R&D) activities in the global lung cancer market It covers active...

April 2013
FROM
Global Lung Cancer Therapeutics Market 2012-2016 Global Lung Cancer Therapeutics Market 2012-2016 - Product Thumbnail Image

Global Lung Cancer Therapeutics Market 2012-2016

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the...

January 2013
FROM
Global Non-small Cell Lung Cancer Drugs Market 2012-2016 Global Non-small Cell Lung Cancer Drugs Market 2012-2016 - Product Thumbnail Image

Global Non-small Cell Lung Cancer Drugs Market 2012-2016

TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the...

January 2013
FROM
Triple Analysis: Lung Cancer, Apoptosis and Peptides Triple Analysis: Lung Cancer, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Lung Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM
Loading Indicator

Our Clients

Our clients' logos